What drove the year-over-year change in net earnings for the third quarter?

While net sales and gross profit saw significant increases, net earnings decreased to $692 million in Q3 2023 from $816 million in Q3 2022. This was primarily due to an increase in selling, general, and administrative expenses as a percentage of net sales, as well as a negative swing in 'Other income (expense), net,' driven by higher interest expense and the absence of a prior year benefit related to a tax audit settlement. Research, development, and engineering expenses also saw a slight decrease.

How did Stryker's different segments perform in terms of sales?

Both of Stryker's reportable segments demonstrated growth. The MedSurg and Neurotechnology segment's net sales increased by 10.5% to $2.86 billion, and the Orthopaedics and Spine segment's net sales grew by 8.4% to $2.05 billion during the third quarter of 2023 compared to the prior year.

What impact did acquisitions have on the financial results?

Stryker completed the acquisition of Cerus Endovascular Limited in May 2023, which contributed to sales growth within the MedSurg and Neurotechnology segment, specifically the Neurovascular business. The company also reported cash used in investing activities for this acquisition. The prior year's third quarter was impacted by the acquisition of Vocera Communications, Inc., which led to higher acquisition and integration-related costs in the prior year's comparative periods.

What is Stryker's current financial position and liquidity outlook?

Stryker maintains a strong financial position with current assets exceeding current liabilities by $3.59 billion as of September 30, 2023. The company generated $2.18 billion in cash from operating activities for the first nine months of 2023. Stryker anticipates supporting its short-term liquidity and operating needs through cash from operations, commercial paper, and existing credit lines, and continues to have strong debt ratings, suggesting continued access to capital markets if needed.

SYK 10-Q Quarterly Report Q3 FY2023 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported strong top-line growth in the third quarter of 2023, with net sales increasing by 9.6% year-over-year to $4.91 billion, driven by both increased unit volume and higher pricing across its major business segments. The company demonstrated improved profitability, with gross profit margin expanding to 64.3% from 62.1% in the prior year's quarter, largely due to favorable volume, mix, and cost efficiencies. Net earnings, however, saw a decrease to $692 million from $816 million in the prior year, resulting in diluted EPS of $1.80 compared to $2.14. This decline in net earnings was influenced by various factors including increased selling, general, and administrative expenses as a percentage of sales and other income/expense fluctuations. The nine-month performance also showcased robust sales growth of 10.8% to $14.68 billion. The company maintained its focus on strategic investments, including the acquisition of Cerus Endovascular Limited, and managing its debt obligations, repaying a significant portion of its term loan. Despite the reported decrease in net earnings for the quarter, the company's underlying operational performance, particularly in sales and gross profit, indicates continued strength and expansion in key markets.

Financial Highlights

51 data points

Beta

Revenue

$4.91B

0.6% Gross Margin

Net Income

$692.00M

0.1% Net Margin

EPS (Diluted)

$1.80

Total Assets

$38.04B

Cash & Equivalents

$1.86B

Free Cash Flow

$902.00M

Financial Statements

Beta

Revenue	$4.91B
Cost of Revenue	$1.75B
Gross Profit	$3.16B
R&D Expenses	$353.00M
SG&A Expenses	$1.71B
Operating Expenses	$2.23B
Operating Income	$931.00M
Net Income	$692.00M
EPS (Basic)	$1.82
EPS (Diluted)	$1.80
Shares Outstanding (Basic)	379.80M
Shares Outstanding (Diluted)	384.00M

Key Highlights

1Net sales grew 9.6% to $4.91 billion for the third quarter of 2023, driven by a 9.3% increase in constant currency, with growth attributed to higher unit volume and pricing.
2Gross profit margin improved to 64.3% from 62.1% in the prior year's quarter, reflecting favorable volume, mix, and manufacturing efficiencies.
3Operating income increased to $931 million from $808 million in the prior year's quarter, with operating margin improving to 19.0% from 18.0%.
4Net earnings for the quarter decreased to $692 million ($1.80 per diluted share) from $816 million ($2.14 per diluted share) in the prior year, impacted by higher SG&A expenses and other income/expense items.
5The MedSurg and Neurotechnology segment showed strong sales growth of 10.5% in the quarter, while the Orthopaedics and Spine segment grew by 8.4%.
6The company repaid $650 million on its term loan and issued €500 of floating rate senior notes during the quarter.
7Stryker completed the acquisition of Cerus Endovascular Limited in May 2023, expanding its neurovascular offerings.

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions